CLINICAL_TRIALS
trial_result
· 2016-09-14
Clinical Trial Update: Dose-finding Study of MT-1303 [Phase 2]
Summary
A Phase 2 dose-finding study of MT-1303 for relapsing-remitting multiple sclerosis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tanabe Pharma Corporation | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED